MMTec, Inc. (MTC) shares fell approximately 16% intraday, closing the prior session at $6.61 before declining toward $5.57.
PSNY shares fell sharply, declining 16.16% intraday as the stock traded near $19.35. Previous session close stood at $23.08.
QCOM shares are down approximately 8% in premarket trading on Monday, June 1, 2026, from a prior session close of $243.29. The primary catalyst is a "sell the news" reaction to Qualcomm CEO Cristiano Amon's Computex 2026 keynote in Taipei, where he unveiled the company's new data center brand "Dragonfly" — but deferred all material product and financial specifics to the June 24 Investor Day.
INTC shares are down approximately 5% in premarket trading on Monday, June 1, 2026, from a prior close of $120.89. The primary driver is renewed concern over Intel's server CPU market share erosion, following a UBS research report highlighting a 370-basis-point sequential decline in Intel's share of the server processor market to 54.9% in Q1 2026.
GRAL shares are down approximately 11% in premarket trading on Monday, June 1, 2026, extending losses that began after the ASCO Annual Meeting data disclosures. The primary catalyst is the full publication of NHS-Galleri trial results at the 2026 ASCO Annual Meeting on May 30, which confirmed that the combined primary endpoint of a statistically significant reduction in Stage III/IV cancers was not met in the aggregate analysis.
OCS shares plunged approximately 34.64% in after-hours and premarket trading on Monday, June 1, 2026, to around $14.84 from a prior regular-session close of $22.70 on May 29. The primary catalyst is the catastrophic failure of OCS-01, the company's lead drug candidate, in both Phase 3 DIAMOND-1 and DIAMOND-2 clinical trials in diabetic macular edema (DME).
WSE shares are down approximately 11% in premarket trading on Monday, June 2, 2026, after closing at $12.47 in the prior session. The primary catalyst is a report by the Bureau of Investigative Journalism revealing that Belgian prosecutors have opened a criminal investigation into Wise over €500 million ($582 million) in suspicious transactions.
Victoria's Secret & Co. is set to report first quarter fiscal 2026 results before market open on June 2, 2026.
Donaldson Company is scheduled to report fiscal third-quarter 2026 results on June 2, 2026, before market open. Analyst consensus calls for earnings per share of $1.05, up 6.1% from $0.99 in the year-ago quarter.
Ulta Beauty is scheduled to report first quarter fiscal 2026 results on June 2, 2026, after market close. Consensus revenue estimate stands at approximately $3.08 billion, reflecting about 8% year-over-year growth.
Dollar General is scheduled to report fiscal first-quarter 2026 results on June 2, 2026, covering the period ended May 1, 2026. Analyst consensus points to earnings per share of approximately $1.49 to $1.90, with revenue estimates near $10.82 billion.
Palo Alto Networks is set to report fiscal third quarter 2026 results on June 2, 2026, after market close. Analysts expect continued revenue growth driven by cybersecurity demand and the recent CyberArk acquisition.
Fourth quarter fiscal 2026 revenue reached $1.75 billion, down 4.8% year-over-year, with full-year revenue at $7.26 billion. Adjusted diluted earnings per share for the quarter hit $2.62, beating analyst expectations, while full-year adjusted diluted EPS came in at $10.75.
Credo Technology Group Holding Ltd is scheduled to report fourth quarter and fiscal year 2026 results after market close on June 1, 2026. Analyst consensus points to Q4 2026 revenue of approximately $432 million and earnings per share of about $0.79.
Hewlett Packard Enterprise is set to report fiscal second-quarter 2026 results after market close on June 1, 2026. Analysts expect earnings per share of approximately $0.54, reflecting continued growth momentum.
Pioneer Power Solutions, Inc. (PPSI) stock rose approximately +47% over the past 30 days, moving from around $3.68 to $5.42 amid elevated trading volume.
Pioneer Power Solutions, Inc. (PPSI) stock rose approximately +47% over the past 30 days, moving from around $3.68 to $5.42 amid elevated trading volume.
Fate Therapeutics (FATE) stock rose approximately +129% over the past 30 days, driven primarily by positive clinical pipeline updates and a first-quarter earnings beat. Over the past quarter, the stock advanced roughly +92%, reflecting sustained momentum from biotech sector developments and company-specific progress in cellular immunotherapies.
Fate Therapeutics (FATE) stock rose approximately +129% over the past 30 days, driven primarily by positive clinical pipeline updates and a first-quarter earnings beat. Over the past quarter, the stock advanced roughly +92%, reflecting sustained momentum from biotech sector developments and company-specific progress in cellular immunotherapies.
NanoViricides (NNVC) stock rose approximately 46% over the past 30 days, driven by increased trading volume and positive momentum in clinical-stage biotech developments. Over the past quarter, the stock advanced more than 80%, reflecting broader recovery from earlier lows amid ongoing pipeline progress.